Enanta Pharmaceuticals (ENTA) Enterprise Value (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Enterprise Value came in at -$163.8 million in Q1 2026, up 15.31% YoY from -$142.0 million in Q1 2025, and up 11.88% on a QoQ basis from -$185.8 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Enterprise Value (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Enterprise Value data on file, last reported at -$163.8 million in Q1 2026.
- Quarterly Enterprise Value rose 15.31% year-over-year to -$163.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$163.8 million (up 15.31% YoY) and the FY2025 annual result came in at -$188.9 million, down 399.1% from the prior year.
- Enterprise Value climbed to -$163.8 million in Q1 2026, from -$185.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$37.8 million in Q3 2024 to a low of -$386.6 million in Q2 2023.
- A 5-year average of -$210.5 million and a median of -$214.5 million in 2022 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 80.52% in 2025, down 399.1% in 2025.
- Tracing ENTA's Enterprise Value over 5 years: stood at -$214.5 million in 2022, then sank by 57.2% to -$337.2 million in 2023, then jumped by 35.73% to -$216.7 million in 2024, then gained by 14.23% to -$185.8 million in 2025, then rose by 11.88% to -$163.8 million in 2026.
- The last three Enterprise Value figures came in at -$163.8 million (Q1 2026), -$185.8 million (Q4 2025), and -$188.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | -189.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -189.51 Mn |
| Mar 31, 2026 | -163.77 Mn |
| Dec 31, 2025 | -185.85 Mn |
| Sep 30, 2025 | -188.86 Mn |
| Jun 30, 2025 | -44.81 Mn |
| Mar 31, 2025 | -193.38 Mn |
| Dec 31, 2024 | -216.69 Mn |
| Sep 30, 2024 | -37.84 Mn |
| Jun 30, 2024 | -230.09 Mn |
| Mar 31, 2024 | -300.31 Mn |
| Dec 31, 2023 | -337.15 Mn |
| Sep 30, 2023 | -85.39 Mn |
| Jun 30, 2023 | -386.59 Mn |
| Mar 31, 2023 | -210.08 Mn |
| Dec 31, 2022 | -214.47 Mn |
| Sep 30, 2022 | -249.23 Mn |
| Jun 30, 2022 | -253.29 Mn |
| Mar 31, 2022 | -280.33 Mn |
| Dec 31, 2021 | -259.05 Mn |
| Sep 30, 2021 | -244.00 Mn |